Recent regulatory filings have detailed insider trading activity involving Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, Inc. (NASDAQ: APGE). On May 6, 2026, Mr. Dambkowski engaged in a series of transactions that included both the acquisition of shares through option exercises and the sale of common stock valued at approximately $462,784.
Transaction Details and Execution
The disposals were carried out in multiple stages. According to a Form 4 filing, Mr. Dambkowski sold a total of 5,500 shares of Apogee Therapeutics common stock. The first portion of these sales involved 3,700 shares, which were sold at a weighted average price of $83.92 per share. These transactions took place within a price spectrum ranging from $83.35 to $84.28 per share. A second tranche of the sale consisted of 1,800 shares, sold at a weighted average price of $84.60 per share, with individual transaction prices falling between $84.44 and $84.69 per share.
These sales were not spontaneous but were executed pursuant to a Rule 10b5-1 trading plan that had been established on September 22, 2025. Prior to the sale, Mr. Dambkowski exercised stock options to acquire 4,125 shares of common stock at an exercise price of $22.86 per share, a transaction valued at $94,297.
Following these activities, Mr. Dambkowski maintains a direct holding of 207,023 shares of Apogee Therapeutics common stock. Furthermore, he holds derivative securities that grant him the right to purchase an additional 123,040 shares of common stock. The options exercised on May 6 were part of a broader grant totaling 175,345 shares, which are scheduled to vest in equal monthly installments over forty-eight months through December 18, 2027, contingent upon his continued service at the firm.
Market Context and Financial Position
Apogee Therapeutics' stock has experienced significant movement, trading at $83.03 at the time of these reports, representing a 123% increase over the previous year. However, valuation discrepancies exist; while some analysts are bullish, an analysis from InvestingPro suggests that shares may be overvalued relative to Fair Value estimates, potentially placing the company on a list of highly overvalued entities.
The company's financial standing is characterized by a "GOOD" health rating, even as it navigates a period without profitability. Over the last twelve months, the company reported earnings per share of -$4.22. In terms of liquidity and capital structure, Apogee Therapeutics recently finalized a public offering of 5.75 million common shares at a price of $70.00 per share. This move, which included the full exercise of underwriters' options for an additional 750,000 shares, raised gross proceeds of approximately $403 million. After accounting for commissions, underwriting discounts, and estimated expenses, the net proceeds are expected to be roughly $377.4 million.
Analyst Perspectives and Pipeline Outlook
The biotechnology sector's interest in Apogee Therapeutics is evidenced by recent analyst activity. Rothschild Redburn initiated coverage with a "Buy" rating and a price target of $140.00, citing the company's work on therapeutics for immunology indications. BTIG reiterated its "Buy" rating with a $137.00 target, pointing toward positive data presented recently. Additionally, Mizuho adjusted its price target upward from $105 to $110 while maintaining an "Outperform" rating, driven by favorable data regarding zumilokibart in the treatment of atopic dermatitis.